Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity DrugsNews DeskApril 17, 20260 Kailera Therapeutics believes it can stand out in a crowded and competitive market for obesity medicines. Global clinical trials underway…
Kailera Plans IPO for Obesity Drug That Could Top Lilly’s ZepboundNews DeskMarch 30, 20260 Kailera Therapeutics isn’t the only company developing an obesity drug that hits multiple targets for weight loss, but the clinical-stage…